Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2022 Jan 21

PMID 35057001

Authors

Eliza Rocha Gomes

Marina Santiago Franco

Affiliations

Soon will be listed here.

Abstract

Cancer is responsible for a significant proportion of death all over the world. Therefore, strategies to improve its treatment are highly desired. The use of nanocarriers to deliver anticancer treatments has been extensively investigated and improved since the approval of the first liposomal formulation for cancer treatment in 1995. Radiotherapy (RT) is present in the disease management strategy of around 50% of cancer patients. In the present review, we bring the state-of-the-art information on the combination of nanocarrier-assisted delivery of molecules and RT. We start with formulations designed to encapsulate single or multiple molecules that, once delivered to the tumor site, act directly on the cells to improve the effects of RT. Then, we describe formulations designed to modulate the tumor microenvironment by delivering oxygen or to boost the abscopal effect. Finally, we present how RT can be employed to trigger molecule delivery from nanocarriers or to modulate the EPR effect.

Citing Articles

Enhancing the Inhibition of Breast Cancer Growth Through Synergistic Modulation of the Tumor Microenvironment Using Combined Nano-Delivery Systems.

Wu J, Lu Q, Zhao J, Wu W, Wang Z, Yu G Int J Nanomedicine. 2024; 19:5125-5138.

PMID: 38855730 PMC: 11162247. DOI: 10.2147/IJN.S460874.

Engineered nanomaterials trigger abscopal effect in immunotherapy of metastatic cancers.

Xia Y, Yang R, Zhu J, Wang H, Li Y, Fan J Front Bioeng Biotechnol. 2022; 10:890257.

PMID: 36394039 PMC: 9643844. DOI: 10.3389/fbioe.2022.890257.

Delivery of Molecules Using Nanoscale Systems for Cancer Treatment and/or Diagnosis.

Santiago Franco M, Youn Y Pharmaceutics. 2022; 14(4).

PMID: 35456689 PMC: 9028462. DOI: 10.3390/pharmaceutics14040851.

References

Slatkin D, Spanne P, Dilmanian F, Sandborg M . Microbeam radiation therapy. Med Phys. 1992; 19(6):1395-400. DOI: 10.1118/1.596771. View

Bouchet A, Lemasson B, Le Duc G, Maisin C, Brauer-Krisch E, Siegbahn E . Preferential effect of synchrotron microbeam radiation therapy on intracerebral 9L gliosarcoma vascular networks. Int J Radiat Oncol Biol Phys. 2010; 78(5):1503-12. DOI: 10.1016/j.ijrobp.2010.06.021. View

Bouchet A, Lemasson B, Christen T, Potez M, Rome C, Coquery N . Synchrotron microbeam radiation therapy induces hypoxia in intracerebral gliosarcoma but not in the normal brain. Radiother Oncol. 2013; 108(1):143-8. DOI: 10.1016/j.radonc.2013.05.013. View

Baumann M, Ebert N, Kurth I, Bacchus C, Overgaard J . What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond. Mol Oncol. 2020; 14(7):1577-1585. PMC: 7332208. DOI: 10.1002/1878-0261.12731. View

Bartzsch S, Cummings C, Eismann S, Oelfke U . A preclinical microbeam facility with a conventional x-ray tube. Med Phys. 2016; 43(12):6301. PMC: 5965367. DOI: 10.1118/1.4966032. View

Wainford R, Weaver R, Stewart K, Brown P, Hawksworth G . Cisplatin nephrotoxicity is mediated by gamma glutamyltranspeptidase, not via a C-S lyase governed biotransformation pathway. Toxicology. 2008; 249(2-3):184-93. DOI: 10.1016/j.tox.2008.05.006. View

Gong L, Zhang Y, Liu C, Zhang M, Han S . Application of Radiosensitizers in Cancer Radiotherapy. Int J Nanomedicine. 2021; 16:1083-1102. PMC: 7886779. DOI: 10.2147/IJN.S290438. View

Sadeghi N, Kok R, Bos C, Zandvliet M, Geerts W, Storm G . Hyperthermia-triggered release of hypoxic cell radiosensitizers from temperature-sensitive liposomes improves radiotherapy efficacy in vitro. Nanotechnology. 2019; 30(26):264001. DOI: 10.1088/1361-6528/ab0ce6. View

Bazyar S, Inscoe C, OBrian E, Zhou O, Lee Y . Minibeam radiotherapy with small animal irradiators; in vitro and in vivo feasibility studies. Phys Med Biol. 2017; 62(23):8924-8942. DOI: 10.1088/1361-6560/aa926b. View

10.

Daguenet E, Louati S, Wozny A, Vial N, Gras M, Guy J . Radiation-induced bystander and abscopal effects: important lessons from preclinical models. Br J Cancer. 2020; 123(3):339-348. PMC: 7403362. DOI: 10.1038/s41416-020-0942-3. View

11.

Zhang M, Hagan 4th C, Foley H, Tian X, Yang F, Au K . Co-delivery of etoposide and cisplatin in dual-drug loaded nanoparticles synergistically improves chemoradiotherapy in non-small cell lung cancer models. Acta Biomater. 2021; 124:327-335. PMC: 9083847. DOI: 10.1016/j.actbio.2021.02.001. View

12.

Santiago Franco M, Gomes E, Roque M, Oliveira M . Triggered Drug Release From Liposomes: Exploiting the Outer and Inner Tumor Environment. Front Oncol. 2021; 11:623760. PMC: 8008067. DOI: 10.3389/fonc.2021.623760. View

13.

Song G, Liang C, Yi X, Zhao Q, Cheng L, Yang K . Perfluorocarbon-Loaded Hollow Bi2Se3 Nanoparticles for Timely Supply of Oxygen under Near-Infrared Light to Enhance the Radiotherapy of Cancer. Adv Mater. 2016; 28(14):2716-23. DOI: 10.1002/adma.201504617. View

14.

Garibaldi C, Jereczek-Fossa B, Marvaso G, Dicuonzo S, Rojas D, Cattani F . Recent advances in radiation oncology. Ecancermedicalscience. 2017; 11:785. PMC: 5718253. DOI: 10.3332/ecancer.2017.785. View

15.

Wilson G, Bentzen S, Harari P . Biologic basis for combining drugs with radiation. Semin Radiat Oncol. 2005; 16(1):2-9. DOI: 10.1016/j.semradonc.2005.08.001. View

16.

Morales-Orue I, Chicas-Sett R, Lara P . Nanoparticles as a promising method to enhance the abscopal effect in the era of new targeted therapies. Rep Pract Oncol Radiother. 2018; 24(1):86-91. PMC: 6251334. DOI: 10.1016/j.rpor.2018.11.001. View

17.

Islam R, Maeda H, Fang J . Factors affecting the dynamics and heterogeneity of the EPR effect: pathophysiological and pathoanatomic features, drug formulations and physicochemical factors. Expert Opin Drug Deliv. 2021; 19(2):199-212. DOI: 10.1080/17425247.2021.1874916. View

18.

Shafei A, El-Bakly W, Sobhy A, Wagdy O, Reda A, Aboelenin O . A review on the efficacy and toxicity of different doxorubicin nanoparticles for targeted therapy in metastatic breast cancer. Biomed Pharmacother. 2017; 95:1209-1218. DOI: 10.1016/j.biopha.2017.09.059. View

19.

Graham K, Unger E . Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment. Int J Nanomedicine. 2018; 13:6049-6058. PMC: 6177375. DOI: 10.2147/IJN.S140462. View

20.

Sabatasso S, Fernandez-Palomo C, Hlushchuk R, Fazzari J, Tschanz S, Pellicioli P . Transient and Efficient Vascular Permeability Window for Adjuvant Drug Delivery Triggered by Microbeam Radiation. Cancers (Basel). 2021; 13(9). PMC: 8123803. DOI: 10.3390/cancers13092103. View